Skip to main content
All CollectionsInformation for Oncologists
FAQ: Oncoshot & Roche Foundation Medicine NGS platform
FAQ: Oncoshot & Roche Foundation Medicine NGS platform

More information on how Oncoshot lets you use genomic information to accelerate research and help patients

Dr Huren Sivaraj avatar
Written by Dr Huren Sivaraj
Updated over a week ago

What services does Oncoshot’s NGS platform offer oncologists?

Oncologists who use Roche Foundation Medicine’s (FMI) next-generation sequencing (NGS) services can now receive automatic notifications on new and updated cancer patient profiles that contain precise genomic information. Using Oncoshot’s patient-to-trial matching tool, oncologists can then match patients to cancer clinical trials, or gain specific quantifiable insights on whether their patient populations are suitable for clinical trials they may be conducting. Such insights can also be used to plan future clinical trials.

What problems does your platform solve, for oncologists?

The digital platform bridges service and data gaps caused by relying on hard copies of genomic reports, which can only accurately match patients to trials at a given point in time. We offer real-time matches, based on up-to-date genomic information, as well as Oncoshot’s global database of cancer trials. Our platform’s concise insights can show you at a glance, whether there are specific cancer patients who may be eligible for enrolment in your cancer trials, thus leading to greater efficiency - both time- and cost-wise.

How does Oncoshot’s trial registry differ from others I can find online?

Most trial registries are ill-maintained and do not competently capture the status of cancer trials within Asia, whereas Oncoshot’s is regularly updated. Updates are provided by trial sites and sponsors that are committed to creating greater awareness of ongoing trials and accelerating enrolment.

When does a patient’s genomic data enter the NGS platform?

When a report is first generated by Roche Foundation Medicine, it is sent to the ordering physician. The Roche Foundation Medicine local office then works with Oncoshot to ensure that a de-identified profile using clinical and FMI alphanumeric IDs is entered onto Oncoshot’s secure system. This digitised profile will then be shared with the oncologist for review, typically within 24 hours.

What sort of patient information is captured?

Data is initially captured based on information available on the Roche Foundation Medicine report. Oncologists have the flexibility to further modify this information for better trial matching capabilities.

How can I be certain that the data captured is accurate?

Oncologists have the opportunity to review and edit profiles of their individual patients, as well as enter more detailed notes, once they have been submitted by Roche Foundation Medicine. The updated profiles are then sent to Roche Foundation Medicine through our platform.

What types of insights does the NGS platform offer, to allow cancer clinics/hospitals to conduct feasibility assessments?

Oncoshot offers population-level insights on how cancer patients match trials they are conducting. This includes a detailed breakdown of patients, across our database, according to their specific tumour mutations and cancer diagnoses.

How is my patient’s privacy protected?

Patient profiles are de-identified before being stored on Oncoshot’s secure platform, thus protecting their privacy.

Do I need to obtain informed consent from my patient to use his/her de-identified data?

There are two separate consent forms, one from FMI and one from Oncoshot, that should be completed before using the service.

How does the NGS platform help elevate cancer research?

Through the platform, Oncoshot helps oncologists and cancer clinics to build their own digital repositories of genomic information that offers a clear picture of cancer populations in Singapore and beyond. With a better understanding of genomic profile frequencies, we can guide leading cancer clinics towards introducing more precision medicine based trials to improve their patients’ clinical outcomes.

Are there plans to refine the NGS platform?

Oncoshot is currently looking into offering more advanced analytics capabilities based on expanded data fields. We will eventually be able to go beyond gene-level information to provide alteration details, as well as biomarkers including relevant immune markers.

Did this answer your question?